fbpx An update on Mmr | Page 165 | Science in the net

An update on Mmr

Primary tabs

Read time: 1 min

Measles, mumps and rubella outbreaks still represent an healthcare issue, even though major advancements have been done towards their eradication. A poor inclination towards Mmr (measles-mumps-rubella) vaccination may constitute a major cause of increased risk to contract one of these diseases amongst specific population groups like migrants, alternative medicine users, some religious groups, healthcare professionals.
Information on Mmr vaccines coverage amongst these and others “hard-to-reach” groups was included in a document made and published Ecdc in range of the European project Venice II (Vaccine European New Integrated Collaboration Effort II). Main aim of the document was to provide a complete review of measles, mumps and rubella focuses which have been reported in the last twenty years in Europe.

Autori: 
Sezioni: 
Indice: 
Vaccination

prossimo articolo

The Bioeconomy strategy in Horizon 2020

What the economic crisis has clearly shown is that Europe cannot afford its economic growth with low R&D manufacturing products. Science and enterprises must merge into hi-tech outcomes to become markets leaders. The European Union is pushing a lot on the bioeconomy sector, namely businesses based on biotechnology. But what is exactly bioeconomy? Is it so important nowadays in Europe? And what is the situation in Italy?

What is a bioeconomy